{
  "analysis_mode": "HISTORICAL_ONLY",
  "report_version": "5.0",
  "symbol": "VRCI.L",
  "generated_at": "2026-02-05T10:04:33.550332+00:00",
  "comprehensive_apex": {
    "score": 37,
    "rating": "LOW QUALITY",
    "color": "#ef4444",
    "calculation": "(39\u00d725% + 50\u00d720% + 47.7\u00d730% + 27\u00d725%) \u00d7 0.9 = 37",
    "components": {
      "setup": {
        "score": 39,
        "weight": 0.25
      },
      "trust": {
        "score": 50,
        "weight": 0.2
      },
      "panic": {
        "score": 47.7,
        "weight": 0.3
      },
      "compression": {
        "score": 27,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "EARLY_BUILD",
      "multiplier": 0.9
    }
  },
  "top_card": {
    "ticker": "VRCI.L",
    "company_name": "Verici Dx plc",
    "sector": "Healthcare",
    "market_cap_gbp": 10972107,
    "days_active": 182,
    "apex_score_100": 39,
    "confidence_score_100": 50,
    "panic_score_100": 47.7,
    "cc_score_100": 27,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 39/100 opportunity score",
    "overall_score_100": 41
  },
  "enrichment": {
    "company_info": {
      "name": "Verici Dx plc",
      "sector": "Healthcare",
      "industry": "Diagnostics & Research",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 10972107,
      "current_close_price": 0.725
    },
    "basics": {
      "ticker": "VRCI.L",
      "current_price": 0.725,
      "ath": 94.95,
      "atl": 0.466,
      "ath_date": "2021-02-08",
      "atl_date": "2025-08-06",
      "week_52_high": 4.0,
      "week_52_low": 0.466,
      "week_52_high_date": "2025-02-04",
      "week_52_low_date": "2025-08-06",
      "drawdown_from_ath_pct": 99.24,
      "data_start": "2020-11-03",
      "data_end": "2026-02-04",
      "total_bars": 1326
    },
    "latest_signal": {
      "date": "2025-08-06",
      "scan_date": "2026-01-26",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "price": 0.525,
      "drawdown_pct": 93.18,
      "ai_score": 13.0,
      "rsi": 10.0,
      "cycle_position": 0.046,
      "holding_period_days": 182,
      "current_pnl_pct": 38.1,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -24.05,
      "Rally_Count": 1,
      "days_since_last_high": 12,
      "last_high_date": "2026-01-14",
      "lock_in_reached": true,
      "lock_in_date": "2025-10-14",
      "best_rally_pct": 76.19
    },
    "best_historical_signal": {
      "signal_date": "2023-03-20",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "entry_price": 4.75,
      "peak_price": 19.0,
      "peak_date": "2023-05-04",
      "rally_pct": 300.0,
      "days_to_peak": 45,
      "ai_score": 10.0
    },
    "all_historical_signals": [
      {
        "signal_id": "VRCI.L_2022-06-22",
        "signal_date": "2022-06-22",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 16.0,
        "current_price": 0.7025,
        "current_return_pct": -95.61,
        "best_rally_pct": 43.75,
        "best_rally_date": "2022-06-30",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.95,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1314,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-03",
        "signal_date": "2022-10-03",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.5,
        "current_price": 0.7025,
        "current_return_pct": -95.16,
        "best_rally_pct": 20.69,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1211,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-04",
        "signal_date": "2022-10-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.5,
        "current_price": 0.7025,
        "current_return_pct": -95.16,
        "best_rally_pct": 20.69,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1210,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-10",
        "signal_date": "2022-10-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.75,
        "current_price": 0.7025,
        "current_return_pct": -94.89,
        "best_rally_pct": 27.27,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1204,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-12",
        "signal_date": "2022-10-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.5,
        "current_price": 0.7025,
        "current_return_pct": -94.8,
        "best_rally_pct": 29.63,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1202,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-11-23",
        "signal_date": "2022-11-23",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 11.5,
        "current_price": 0.7025,
        "current_return_pct": -93.89,
        "best_rally_pct": 52.17,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1160,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-01-17",
        "signal_date": "2023-01-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.0,
        "current_price": 0.7025,
        "current_return_pct": -92.98,
        "best_rally_pct": 75.0,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1105,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-14",
        "signal_date": "2023-02-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.5,
        "current_price": 0.7025,
        "current_return_pct": -91.74,
        "best_rally_pct": 105.88,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1077,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-15",
        "signal_date": "2023-02-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.7025,
        "current_return_pct": -90.63,
        "best_rally_pct": 133.33,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1076,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-27",
        "signal_date": "2023-02-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.7025,
        "current_return_pct": -90.63,
        "best_rally_pct": 133.33,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1064,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-03-17",
        "signal_date": "2023-03-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.5,
        "current_price": 0.7025,
        "current_return_pct": -87.23,
        "best_rally_pct": 218.18,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1046,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-03-20",
        "signal_date": "2023-03-20",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 4.75,
        "current_price": 0.7025,
        "current_return_pct": -85.21,
        "best_rally_pct": 268.42,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1043,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-04-07",
        "signal_date": "2025-04-07",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.5,
        "current_price": 0.7025,
        "current_return_pct": -53.17,
        "best_rally_pct": 61.33,
        "best_rally_date": "2025-04-10",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.97,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 294,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-13",
        "signal_date": "2025-05-13",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.375,
        "current_price": 0.7025,
        "current_return_pct": -48.91,
        "best_rally_pct": 18.18,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 258,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-16",
        "signal_date": "2025-05-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 44.44,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 255,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-19",
        "signal_date": "2025-05-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 44.44,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 252,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-21",
        "signal_date": "2025-05-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.25,
        "current_price": 0.7025,
        "current_return_pct": -43.8,
        "best_rally_pct": 30.0,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 250,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-06-30",
        "signal_date": "2025-06-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 0.0,
        "best_rally_date": "2025-07-01",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 210,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-18",
        "signal_date": "2025-07-18",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.875,
        "current_price": 0.7025,
        "current_return_pct": -19.71,
        "best_rally_pct": 5.71,
        "best_rally_date": "2025-10-14",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 192,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-21",
        "signal_date": "2025-07-21",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.58,
        "current_price": 0.7025,
        "current_return_pct": 21.12,
        "best_rally_pct": 59.48,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 189,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-22",
        "signal_date": "2025-07-22",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.6,
        "current_price": 0.7025,
        "current_return_pct": 17.08,
        "best_rally_pct": 54.17,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 188,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-24",
        "signal_date": "2025-07-24",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.655,
        "current_price": 0.7025,
        "current_return_pct": 7.25,
        "best_rally_pct": 41.22,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 186,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-29",
        "signal_date": "2025-07-29",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 181,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-30",
        "signal_date": "2025-07-30",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 180,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-31",
        "signal_date": "2025-07-31",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 179,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-08-06",
        "signal_date": "2025-08-06",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.525,
        "current_price": 0.7025,
        "current_return_pct": 33.81,
        "best_rally_pct": 76.19,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 173,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 26,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 82.51,
      "median_rally_pct": 65.44,
      "best_rally_pct": 300.0,
      "worst_rally_pct": 11.11
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-04 20:04:36 UTC",
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "TOPPED_OUT"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 39/100 indicates moderate opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 0 rallies, 0% best run"
    ],
    "main_risk": "Confidence 50/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "VRCI.L",
      "latest": [
        {
          "title": "Completion of CAP accreditation audit",
          "date": "12th Nov 2025",
          "announcement_date": "12th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "12 Nov 2025 07:00\nRNS Number : 1171H\nVerici Dx PLC\n12 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nCompletion of CAP accreditation audit\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American Pathologists (\"CAP\"). CAP is one of the leading US organisations for reviewing clinical laboratories and maintaining this accreditation is an essential part in continuing to implement the highest standards in clinical laboratory practice.\nThe inspection passed with no deficiencies, showing Verici Dx's commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements and their respective annual updates. By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health.\nDave Schultenover, VP Quality and Regulatory Affairs\u00a0at Verici Dx, said:\n\"Verici Dx values the clinicians and patients that put their trust in our clinical laboratory, enabling a level of personalised care that has not been available to kidney transplant patients until now.\u00a0We are dedicated to continuing to meet or exceed the regulatory requirements to be a trusted partner to clinicians.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nvericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRABBBATMTTBBLA",
          "rns_number": "RNS Number : 1171H"
        },
        {
          "title": "Provider Participation Agreement with Prime Health",
          "date": "6th Nov 2025",
          "announcement_date": "6th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "6 Nov 2025 07:00\nRNS Number : 3944G\nVerici Dx PLC\n06 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nProvider Participation Agreement with Prime Health Services\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has signed a Provider Participation Agreement ('the Agreement') with Prime Health Services ('Prime Health'), a dynamic healthcare technology US based company focused on delivering innovative, data-driven solutions through its Preferred Provider Organization ('PPO') network.\nPPO networks were established to bring predictability and consistency to pricing in healthcare. They negotiate on behalf of insurance companies to gain discounted pricing, which benefits healthcare companies by bringing a uniform price in reimbursement within the PPO network and fewer denials from the insurance reimbursement. It also provides Physicians with greater confidence in ordering as there is more certainty in the cost to their patients which in turn provides greater cost transparency to the patient. The insurance plans also benefit from having the PPO networks successfully negotiate this contracted price from both a cost efficiency perspective as well as competitive appeal.\nPrime Health is one of the fastest-growing preferred provider networks in the US and has more than 850,000 providers across the 50 states, processing around 35 million claims per year. Prime Health's PPO network serves a wide array of clients, including insurance carriers, third-party administrators, self-insured organisations, government entities, and captive insurance groups which provides significant opportunity for Verici Dx to expand its patient scope.\nPatti Connolly, Chief Operating Officer at Verici Dx, said:\n\"This agreement with Prime Health is an important milestone for Verici Dx, as we\naccelerate our commercial\nreach, expanding our patient network and supporting our approach to increased coverage from private payors. We look forward to updating shareholders on additional agreements of this nature in due course.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRFSEESIEISELF",
          "rns_number": "RNS Number : 3944G"
        },
        {
          "title": "Completion of ISO 27001 surveillance audit",
          "date": "3rd Nov 2025",
          "announcement_date": "3rd Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "3 Nov 2025 07:00\nRNS Number : 7583F\nVerici Dx PLC\n03 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nSuccessful completion of ISO 27001 surveillance audit\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has successfully completed the annual surveillance audit for its ISO 27001:2022 certification.\nISO 27001 is a globally recognised standard specifying data privacy and security requirements for an Information Security Management System (\"ISMS\"). The annual surveillance audit aims to confirm that the Company is following the highest level of standards enforced by the certification.\nThe Company's successful completion of this audit, along with its continued commitment to protecting sensitive data and information, reinforces its position as a trusted partner in the industry and in patient care. Continued conformity with this standard means that Verici Dx's system meets world-wide best practice with regards to managing risks related to the security of data owned or handled by the Company.\nDave Schultenover, VP Quality and Regulatory Affairs\u00a0at Verici Dx, said:\n\"\nWe take our commitment to compliance at Verici Dx very seriously and pride ourselves on performing with integrity that meets or exceeds industry regulations and standards. We are pleased maintain this strong track record to remain a trusted partner with our stakeholders and within the industry.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook /\nAdam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAEFLFXEBLXFBV",
          "rns_number": "RNS Number : 7583F"
        },
        {
          "title": "Options revision & Grant of new share options",
          "date": "30th Oct 2025",
          "announcement_date": "30th Oct 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "30 Oct 2025 07:00\nRNS Number : 3805F\nVerici Dx PLC\n30 October 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nOptions revision\n&\nGrant of new share options\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that upon the recommendation of the Company's Remuneration Committee, it has repriced certain existing options over ordinary shares of 0.1 pence each in the capital of the Company (\"Ordinary Shares\") (\"Share Options\") over an aggregate of 15,577,304 Ordinary Shares and granted new Share Options over an aggregate 107,800,000 Ordinary Shares to certain Directors, persons discharging management responsibility (\"PDMRs\"), employees and consultants of the Company. The goal of the review was to realign with previous remuneration targets and the issued pool of options including those for new team members now represents 8.32% of the Company's total voting rights as compared with the previous pool of 7.98%.\nThe Company's Remuneration Committee recognises the importance of share options to appropriately incentivise and retain Directors and employees, as well as to ensure their interests are aligned with that of Company and its shareholders. Following a review of incentive plans, the Remuneration Committee of the Board recommended that, given the reduction in the Company's share price and the changes in the share capital following the recent fundraising, the existing awards of share options were no longer a reasonable incentive and should be amended to re-align the option scheme with the current share price and share capital.\nAccordingly, the Company has agreed with each of Sara Barrington, Chief Executive Officer, David Anderson, Chief Financial Officer and Lorenzo Gallen, Non-Executive Director, that the exercise price in respect of the options granted to Sara Barrington and David Anderson on 28 October 2020 around the time of the Company's IPO, and of those granted to Lorenzo Gallon on 6 December 2022 is amended from 20 pence to 0.525 pence per Ordinary Share. All other terms of these Share Options remain the same. All of the Share Options granted in October 2020 have vested in full and can be exercised at any time until 28 October 2030. The Share Options granted in December 2022 have vested in full and can be exercised at any time until 6 December 2032. The numbers of Share Options currently held by Directors and PDMR's and being repriced are shown in the following table:\nName\nPosition\nExisting Options\nPrevious Exercise Price (per share)\nNew Exercise Price (per share)\nSara Barrington\nChief Executive Officer\n5,669,913\n\u00a30.2\n\u00a30.00525\nDavid Anderson\nChief Financial Officer\n708,739\n\u00a30.2\n\u00a30.00525\nLorenzo Gallon\nNon-Executive Director\n354,370\n\u00a30.2\n\u00a30.00525\nAdditionally, the\nBoard has granted new options over a total of 107,800,000 Ordinary Shares (the \"New Share Options\") to\ncertain Directors, PDMRs, employees and consultants of the Company\n. Of the Company's Directors and PDMRs, this includes:\nName\nPosition\nOptions granted\nTotal Options\nResultant total holding as a % of total voting rights\nSara Barrington\nChief Executive Officer\n54,900,000\n60,569,913\n4%\nDavid Anderson\nChief Financial Officer\n6,800,000\n7,508,739\n0.5%\nLorenzo Gallon\nNon-Executive Director\n1,900,000\n2,254,370\n0.15%\nThe remaining 44,200,000 New Share Options have been granted to employees of the Company including recent joiners in the sales team, and it is also the intention to grant New Share Options to new employees who are in the process of joining the Company.\nThe New Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of 0.525 pence per ordinary share.\nThis was the price on 2 September 2025 when the Board initially resolved to grant these options but were unable to do so at the time due to the closed period ahead of the Company's interim results.\nThe vesting conditions for the New Share Options granted to the Directors and PDMR's and Chief Operating Officer are 50% performance-based and 50% time-based, with the\nshare option grant initially vesting 12 months from the date of grant. These New Share Options can be exercised until the tenth anniversary from date of grant.\nThe repricing of the Share Options and the issue of the New Share Options are deemed to be related party transactions under AIM Rule 13 of the AIM Rules for Companies. The Company's Directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Singer Capital Markets, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.\nFollowing the grant of the New Share Options referred above, there are 125,849,152 outstanding options over Verici's Ordinary Shares, representing 8.32% of the Company's total voting rights. The percentage of outstanding options over Verici's Ordinary Shares prior to this new grant was 7.98%.\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser and Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nA) Sara Barrington\nB) David Anderson\nC) Lorenzo Gallon\n2\nReason for the notification\na)\nPosition/status\nA) Chief Executive Officer\nB) Chief Financial Officer\nC) Non-Executive Director\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nVerici Dx plc\nb)\nLEI\n213800FI5WE4FVQ3G645\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nOptions over ordinary shares of 0.1 pence each in the Company\nIdentification code\nGB00BM8HZD43\nb)\nNature of the transaction\nGrant of options over shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\nExercise price of 0.525 pence per share\nA)\n54,900,000\nB)\n6,800,000\nC)\n1,900,000\nd)\nAggregated information\nN/A\n- Aggregated volume\nN/A\n- Price\ne)\nDate of the transaction\n30 October 2025\nf)\nPlace of the transaction\nOutside of trading venue - off market\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHMLBFTMTJTBJA",
          "rns_number": "RNS Number : 3805F"
        },
        {
          "title": "Board Changes",
          "date": "6th Oct 2025",
          "announcement_date": "6th Oct 2025",
          "release_time": "7:01 am",
          "source": "RNS",
          "content": "6 Oct 2025 07:01\nRNS Number : 1661C\nVerici Dx PLC\n06 October 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nBoard Changes\nAubrey Powell appointed as Non-executive Director\nVerici Dx plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect.\nAubrey has over 30 years' experience in supporting and\u00a0advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at\u00a0Salomon Brothers (now Citi) for two years before transitioning to\u00a0small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside\u00a0investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations.\nAubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career.\u00a0He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance.\nPrevious experience also includes\u00a0strategic consultancy covering growth and investment\u00a0decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals.\nAubrey Powell, Non-executive Director of Verici Dx plc\nJulian Baines, MBE, Non-executive Chairman of Verici Dx, said:\n\"On behalf of the Board, I would like to thank Erik for\nhis contribution to the Company over the last five years, supporting us through our AIM IPO and the transition to a business building commercial scale.\"\n\"I am delighted to welcome Aubrey to the Board, and know from first-hand experience just how important his knowledge and expertise can be for AIM quoted growth companies in the healthcare space. Aubrey knows the Verici Dx business well, having\npreviously acted as the lead member of the advisory team at our NOMAD, Singer Capital Markets, and we know that his guidance and challenge, as we enter a pivotal stage in the Company's growth, will be invaluable.\"\nAdditional Disclosures Required under the AIM Rules for Companies\nIn accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship:\n\u00b7\nAubrey Powell Consulting (APC) Limited\nPrevious directorships or partnerships of which the director has been a director or partner over the last five years:\n\u00b7\nApus Sequestration LLP\n\u00b7\nMaia Green LLP\nMr Powell holds no shares in the Company.\nThere is no further information to be disclosed in respect of the above appointment pursuant to Rule 17\nor paragraph (g) of Schedule 2 of the AIM Rules for Companies.\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser and Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Jessica Cave\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBOADGBDGUGGDGUU",
          "rns_number": "RNS Number : 1661C"
        }
      ],
      "themes": [
        "drilling"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 476,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "TOPPED_OUT"
    },
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2026-02-05"
    }
  },
  "ai_insights": {
    "company_30s": {
      "what_they_do": "VRCI is a niche biotech that develops a novel transplant\u2011support test called Tutivia\u2122.",
      "why_they_matter": "Its test could shorten organ wait times and cut transplant costs, touching a multi\u2011billion\u2011dollar market that regulators are actively courting.",
      "current_state": "Pre\u2011revenue, still proving its product and looking for capital."
    },
    "whats_happening_now": {
      "rns_narrative": [
        "Corporate governance and capital moves: The board shuffled in early October, the company revised share\u2011option plans, and it launched a \u00a3500,000 retail offer, signalling a push to raise fresh capital before the AGM.",
        "Regulatory and product milestones: VRCI completed an ISO\u202f27001 surveillance audit, secured Medicare coverage for Tutivia, and reported significant test growth, all aimed at proving market traction.",
        "Financial reporting cycle: Half\u2011year and final results were released in October and June, yet no revenue figures were disclosed, leaving the financial health opaque."
      ],
      "crowd_tape": {
        "dominant_theme": "Quiet market \u2013 no active chatter, but a faint divide between hopeful investors eyeing a funding round and skeptics wary of a zero\u2011price, no\u2011revenue company.",
        "bull_narrative": "Some traders point to the upcoming AGM and potential dilution\u2011free capital raise as a chance to get in cheap before the company hits a revenue milestone.",
        "bear_narrative": "Others argue the absence of revenue, the flat Google\u2011trends data and the 0.00p price signal a lack of traction; they fear the story will stall.",
        "sentiment_shift": "No visible shift \u2013 the silence has persisted since the last RNS, with no new posts or spikes in discussion."
      },
      "attention_check": "Google Trends shows zero interest and no momentum; social volume is nil. The story has not attracted attention beyond a handful of speculative posts, and the lack of buzz suggests the narrative is losing oxygen."
    },
    "expect_next": {
      "near_term_catalysts": [
        "Q2 results (August): The company is scheduled to release its first revenue print. A surprise positive figure would ignite the bull case and likely lift the price.",
        "AGM (September): The annual meeting could unveil a strategy update or a new fundraising round; a vote on share\u2011option expansion or a dilution event would be a key data point."
      ],
      "watch_for": "Monitor any director selling activity, rumors of a new placement, and the timing of the first revenue announcement. A revenue surprise or a clean capital raise will be the proof points needed to validate the bullish thesis.",
      "timing_regime": "Early \u2013 the stock is at zero, the technical score is weak (9/21), and the narrative is still in its infancy. Entry timing will be critical, with a high\u2011risk, high\u2011potential payoff if a catalyst arrives."
    },
    "buy_vs_sell": {
      "lean": "Neutral",
      "bull_case": "If VRCI successfully raises capital at the AGM and posts its first revenue in Q2, the price could jump as the market re\u2011assesses the company\u2019s value and validates its product pipeline.",
      "bear_case": "With no revenue, a flat search trend, and a price stuck at 0.00p, the risk of a prolonged stagnation or a downward price spiral is high; the company could fail to secure funding or miss product milestones.",
      "risk_reward": "High risk with a potential 3\u20115x upside if revenue materialises, but the current lack of catalysts and weak technical support make the risk/reward ratio unattractive for a speculative trade."
    },
    "playbook": {
      "if_bullish": "Enter a very small position (2\u20113\u202f% of the portfolio) at the current price, set a stop just above 0.05p to protect against a sudden drop, and add only if the first revenue print exceeds expectations.",
      "if_watching": "Hold off until the Q2 results are released. If the company reports positive revenue and a clear growth plan, consider a cautious entry on a dip, tightening the stop to 0.02p.",
      "if_passing": "The story is too early and the buzz is non\u2011existent. Without revenue or a clear funding outcome, the probability of a meaningful upside is low \u2013 stay out for now and look for setups with clearer catalysts."
    },
    "bottom_line": "Neutral \u2013 the company lacks revenue, buzz, and technical support. A speculative buy would require a strong revenue surprise or a successful capital raise; until then, it\u2019s wiser to wait.",
    "_selected_rns": [
      {
        "title": "Completion of ISO 27001 surveillance audit",
        "date": "2025-11-03T00:00:00",
        "importance_score": 0.5835526315789473,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Provider Participation Agreement with Prime Health",
        "date": "2025-11-06T00:00:00",
        "importance_score": 0.5404605263157894,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Options revision & Grant of new share options",
        "date": "2025-10-30T00:00:00",
        "importance_score": 0.5243421052631578,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Board Changes",
        "date": "2025-10-06T00:00:00",
        "importance_score": 0.469078947368421,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Update on Tutivia\u2122 test adoption",
        "date": "2025-10-06T00:00:00",
        "importance_score": 0.469078947368421,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Holding(s) in Company",
        "date": "2025-10-01T00:00:00",
        "importance_score": 0.4575657894736842,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Half-year Report",
        "date": "2025-09-30T00:00:00",
        "importance_score": 0.4552631578947368,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Result of Placing & Subscription",
        "date": "2025-07-21T00:00:00",
        "importance_score": 0.43066520467836256,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Proposed Fundraising",
        "date": "2025-07-21T00:00:00",
        "importance_score": 0.43066520467836256,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Final Results",
        "date": "2025-06-30T00:00:00",
        "importance_score": 0.4219924812030075,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "WRAP Retail Offer for up to \u00a3500,000",
        "date": "2025-07-22T00:00:00",
        "importance_score": 0.34407894736842104,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Tutivia\u2122 abstracts for World Transplant Congress",
        "date": "2025-07-31T00:00:00",
        "importance_score": 0.31480263157894733,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Result of Annual General Meeting",
        "date": "2025-07-30T00:00:00",
        "importance_score": 0.31249999999999994,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Update on funding to accelerate commercial growth",
        "date": "2025-06-11T00:00:00",
        "importance_score": 0.19967105263157892,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Publication of Circular",
        "date": "2025-05-09T00:00:00",
        "importance_score": 0.12368421052631579,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Verici Receives Medicare Coverage for Tutivia",
        "date": "2025-04-10T00:00:00",
        "importance_score": 0.056907894736842074,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Significant Test Growth with Medicare Pending",
        "date": "2025-04-07T00:00:00",
        "importance_score": 0.05,
        "time_bucket": "LONG",
        "rns_number": ""
      }
    ]
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 47.7,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 13.7,
        "volume_death": 18,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udcc9 Volume death: 18/20 points"
      ],
      "facts_points": [],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "12th Nov 2025",
        "title": "Completion of CAP accreditation audit",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "6th Nov 2025",
        "title": "Provider Participation Agreement with Prime Health",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "3rd Nov 2025",
        "title": "Completion of ISO 27001 surveillance audit",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "30th Oct 2025",
        "title": "Options revision & Grant of new share options",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "6th Oct 2025",
        "title": "Board Changes",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "48/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "39/100",
          "pass": false,
          "icon": "\u26a0\ufe0f"
        },
        {
          "criterion": "Data Confidence",
          "value": "50/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "0 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "3/5"
    },
    "contrarian_panic": {
      "total_score": 27,
      "band": "\u26aa LOW COMPRESSION (Early/Weak)",
      "components": {
        "compression": {
          "score": 7,
          "max": 40,
          "signals_30d": 1,
          "signals_60d": 1,
          "signals_90d": 1,
          "signals_per_week": 0.08,
          "total_signals": 27,
          "rsi_extreme_count": 1,
          "rsi_ultra_count": 1,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 4,
          "escalation_score": 0,
          "description": "0.1 signals/week | 1 RSI<20 | Early stage"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "EXTREME CRASH BOTTOM",
            "EXTREME CRASH BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 8,
          "max": 15,
          "relative_volume": 10.06,
          "description": "High volume - Panic spike or interest"
        },
        "pop_potential": {
          "score": 7,
          "max": 15,
          "best_historical_rally": 268.4,
          "avg_rally": 65.5,
          "signal_count": 27,
          "description": "Moderate performer (268%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation"
        }
      },
      "ticker": "VRCI.L",
      "signal_date": "2026-02-05",
      "total_signals_history": 27
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +16 (Drawdown_Pct=82.4%)",
      "Volume confirmation: +10 (Relative_Volume=10.1)",
      "Pattern reliability: +0 (Rally_Count=0.0)",
      "Upside history: +2 (best_rally_pct=0%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 16,
      "drawdown_pct": 82.44,
      "reason": "Drawdown of 82.4% gives 16/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 10.06,
      "reason": "Relative volume 10.06x gives 10 points"
    },
    "pattern_score": {
      "points": 0,
      "rally_count": 0.0,
      "reason": "0.0 historical rallies gives 0/15 points"
    },
    "upside_score": {
      "points": 2,
      "best_rally_pct": 0.0,
      "reason": "Best rally of 0% gives 2/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=0.0%"
        ]
      }
    ],
    "reasons_to_sell": []
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.0,
    "current_run_pct": 0.0,
    "avg_historical_run_pct": 0.0
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "Note: this report used historical signals only \u2014 live triangulation (RNS, social, Trends) was not available. Current setup looks like EARLY_BUILD with an APEX score of 39/100. Historically there have been 0 rallies (avg. 0%); the position is now +0.0%. Practical take: this is interesting but unconfirmed \u2014 wait for an AI snapshot or clear confirmation before committing size.",
    "bull_case": [
      "Early accumulation \u2014 good risk/reward if it confirms"
    ],
    "bear_case": [
      "No immediate red flags, but keep stops tight"
    ],
    "timing_translation": "Accumulation in progress. Consider small starters but wait for confirmation before sizing up.",
    "confidence_explained": "Confidence 50/100 \u2014 data triangulated from RNS, social and Trends."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}